Plain-English translation of NCT04864145 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study compares two approaches for treating severe aortic regurgitation (a condition where your aortic valve leaks and your heart can't pump blood effectively). Some participants will receive a minimally invasive catheter-based valve implantation—a newer procedure where doctors thread a replacement valve through blood vessels to your heart without opening your chest. Others will receive with several heart medications designed to help your heart work better.
Many older patients and those with serious health conditions are considered too high-risk for traditional open-heart surgery to replace a leaky aortic valve, so they go untreated—which carries a 10–20% yearly risk of death. This trial investigates whether the new catheter-based approach is a safer alternative for these high-risk patients.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the catheter procedure group, you will undergo transcatheter aortic valve implantation—a minimally invasive intervention where doctors insert a replacement valve through a blood vessel without major surgery. If assigned to the medication group, you will receive multiple heart medications (such as blood pressure medications and diuretics) and regular follow-up appointments to monitor your condition. Both groups will have ongoing medical visits to track how well the treatment is working and assess your heart function over time.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
China
Sponsor
Nanjing First Hospital, Nanjing Medical University
Enrollment target
~210 participants
Started
May 2021
Primary completion
December 2026
Age range
60 Years – 90 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jun-Jie Zhang, MD, PhD
Nanjing First Hospital, Nanjing Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.